嵌合抗原受体T细胞治疗女性高发恶性肿瘤的研究进展和挑战  

Advances and challenges of chimeric antigen receptor T cells in the treatment of female high-risk malignant tumors

作　　者：张露[1] 赵乐乐 解思凯 李海鹏 王俊杰 李正红[1] ZHANG Lu;ZHAO Lele;XIE Sikai;LI Haipeng;WANG Junjie;LI Zhenghong(Department of Life Sciences,Bengbu Medical College,Bengbu 233030,China;Department of Preventive Medicine,Bengbu Medical College,Bengbu 233030,China;Department of Psychiatry,Bengbu Medical College,Bengbu 233030,China)

机构地区：[1]蚌埠医学院生命科学院,安徽蚌埠233030 [2]蚌埠医学院公共卫生学院,安徽蚌埠233030 [3]蚌埠医学院精神卫生学院,安徽蚌埠233030

出　　处：《山东第一医科大学（山东省医学科学院）学报》2023年第8期608-612,共5页Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences

基　　金：安徽省重点研究与开发计划(201904a07020019)。

摘　　要：宫颈癌、卵巢癌、子宫内膜癌是临床常见的三种妇科恶性肿瘤,乳腺癌在女性群体高发。现有较为成熟的治疗方案如手术、放疗和化疗等对于晚期、转移性和复发性肿瘤治疗效果难有突破。嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞疗法缘于治疗血液系统恶性肿瘤成效卓著而闻名于世。现将CAR-T疗法应用于女性高发恶性肿瘤方向的国内外研究现状、治疗过程需要解决的问题以及治疗后可能出现的不良反应进行综述。Cervical cancer,ovarian cancer and endometrial cancer are three common gynecological malignancies,and breast cancer has a high incidence in women.The existing more mature treatment schemes,such as surgery,radiotherapy and chemotherapy,are not effective in the treatment of advanced,metastatic and recurrent tumors.Chimeric antigen receptor T(CAR-T)cell therapy is famous for its remarkable effect in the treatment of hematological malignancies.This paper reviews the research status of CAR-T therapy applied to female high incidence malignant tumors at home and abroad,the problems to be solved in the treatment process and the possible adverse reactions after treatment.

关 键 词：嵌合抗原受体T细胞 女性高发恶性肿瘤 妇科恶性肿瘤 过继免疫治疗 肿瘤相关抗原 

分 类 号：R737.3[医药卫生—肿瘤]